Evidence map›Paper›PMID 33543032›Full record

ArticleMatrix biology plus2020

Complexity of matrix phenotypes.

Renato V Iozzo, Achilleas D Theocharis, Thomas Neill, Nikos K Karamanos

Abstract read
In one paragraph

Article in Matrix biology plus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Trends in extracellular matrix biology.Molecular biology reports · 2023
    Review
  7. Article
  8. Review
  9. Review
  10. Frontiers in oncology · 2022
    Article
  11. Article
  12. Extracellular Matrix Biomarkers in Colorectal Cancer.International journal of molecular sciences · 2021
    Review
  13. Article
  14. Article
  15. A functional outside-in signaling network of proteoglycans and matrix molecules regulating autophagy.Matrix biology : journal of the International Society for Matrix Biology · 2021
    Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Renato V IozzoDepartment of Pathology, Anatomy and Cell Biology and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States of America.
Achilleas D TheocharisBiochemistry, Biochemical Analysis and Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece.
Thomas NeillDepartment of Pathology, Anatomy and Cell Biology and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States of America.
Nikos K KaramanosBiochemistry, Biochemical Analysis and Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece.

Funding

NEOPLASTIC MODULATION OF PROTEOGLYCAN METABOLISMR01CA039481 · NCI · UNIVERSITY OF PENNSYLVANIA · PI IOZZO, RENATO V. · 1985 to 2020
$7.1M
The Biology of Perlecan in Cancer and AngiogenesisR01CA047282 · NCI · THOMAS JEFFERSON UNIVERSITY · PI IOZZO, RENATO V. · 1990 to 2019
$5.7M
NCI NIH HHS R01 CA039481NCI NIH HHS R01 CA047282
6 · The paper itself

Abstract

The extracellular matrix is engaged in an ever-evolving and elegant ballet of dynamic reciprocity that directly and bi-directionally regulates cell behavior. Homeostatic and pathophysiological changes in cell-matrix signaling cascades manifest as complex matrix phenotypes. Indeed, the extracellular matrix can be implicated in virtually every known human disease, thus, making it the most critical and dynamic "organ" in the human body. The overall goal of this

Indexed as

ADAM, a disintegrin and metalloproteinasesAGE, advanced glycation end productsAngiogenesisCancerCollagenDDR1, discoidin domain receptor 1ECM, extracellular matrixEGF, epidermal growth factorEGFR, epidermal growth factor receptorEMILIN1, elastin microfibril interfacer 1EMILIN2, elastin microfibril interfacer 2EMT, epithelial-mesenchymal transitionERα, estrogen receptor αERβ, estrogen receptor βGBM, glioblastomaHA, hyaluronanHAS2-AS1, HAS2 antisense 1HAS2, hyaluronan synthase 2HB-EGF, heparin binding EGFHMGA2, high-mobility group AT-Hook 2IBC, inflammatory breast cancerIGF-IR, insulin growth factor I receptorIR-A, insulin receptor ALEKTI, lympho-epithelial Kazal-type inhibitorLOX, lysyl oxidasesLTBP, latent TGFβ-binding proteinsMAGP, microfibril-associated glycoproteinsMethodologiesMET, mesenchymal-epithelial transitionmiR, microRNAMMP, matrix metalloproteinasesOB, osteoblastOI, osteogenesis imperfectaPARs, protease activated receptorsPG, proteoglycansPLL, poly-l-lysineProteoglycansROS, reactive oxygen speciesRTK, receptor tyrosine kinaseSLRP, small leucine rich proteoglycansSSR, solar-simulated radiationTGFβ, transforming growth factor βTNT, tunneling nanotubestPA, tissue-type plasminogen activatoruPA, urokinase-type plasminogen activatorUVR, ultraviolet radiationVEGF, vascular endothelial growth factor

Identifiers

PMID33543032
PMCPMC7852209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.